Premium
Association of polymorphisms within androgen receptor, 5α‐reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men
Author(s) -
Schatzl Georg,
Madersbacher Stephan,
Gsur Andrea,
Preyer Martin,
Haidinger Gerald,
Haitel Andrea,
Vutuc Christian,
Micksche Michael,
Marberger Michael
Publication year - 2002
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.10101
Subject(s) - androgen receptor , prostate cancer , hyperplasia , medicine , prostate , endocrinology , prostate specific antigen , androgen , population , biology , cancer , hormone , environmental health
Abstract BACKGROUND The aim of this study was to assess the impact of polymorphisms of three genes within the androgen pathway on prostate volume, clinical parameters, and endocrine status. METHODS Elderly men with lower urinary tract symptoms underwent clinical and endocrine work‐up. In parallel, polymorphisms within the 5α‐reductase gene (SRD5A2 V89L and A49T), the androgen receptor gene (AR; number of CAG repeats), and the prostate specific antigen (PSA) gene (A → G substitution at position‐158) were determined by polymerase chain reaction and restriction‐length polymorphism analysis by using DNA from peripheral blood. RESULTS A total of 190 men (66.5 ± 9.2 yr) were analyzed. The number of CAG repeats within the AR and the PSA polymorphism revealed no associations to clinical and endocrine parameters. Individuals carrying the mutated SRD5A2 A49T allele (5.3% of the total population) had larger prostates (54.1 vs. 39.3 ml), higher PSA levels (12.2 vs. 4.3 ng/ml), and a 35% reduction in prostatic stroma/epithelial cell ratio. Men with the mutated SRD5A2 V89L gene had lower testosterone levels. CONCLUSIONS In contrast to prostate cancer, polymorphisms within AR and PSA genes do not seem to be of importance for benign prostatic hyperplasia. Polymorphisms within the 5α‐reductase gene are interesting biomarkers for the development of benign prostatic hyperplasia and benign prostatic enlargement. Prostate 52:130–138, 2002. © 2002 Wiley‐Liss, Inc.